Pharmacologic heterogeneity of new anticoagulants;Hétérogénéité pharmacologique des nouveaux anticoagulants

Journal des Maladies Vasculaires

Volumn 36, Issue SUPPL.1, 2011, Pages

  Samama, M M ^a,b   Conard, J ^a   Flaujac, C ^a   Combe, S ^a   Horellou, M H ^a  

^a Institut Cochin   (France)

^b Laboratoire Biomnis   (France)

Author keywords

Apixaban; Dabigatran; Edoxaban; Rivaroxaban

Indexed keywords

APIXABAN; DABIGATRAN ETEXILATE; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; DRUG DERIVATIVE; MORPHOLINE DERIVATIVE; N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE; N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; THIOPHENE DERIVATIVE;

ARTICLE; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; FOOD AND DRUG ADMINISTRATION; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; MOLECULAR WEIGHT; THROMBOEMBOLISM; THROMBOSIS PREVENTION; VEIN THROMBOSIS; DRUG APPROVAL; DRUG CONTRAINDICATION; HIP ARTHROPLASTY; KIDNEY; KNEE ARTHROPLASTY; LIVER; METABOLISM; POSTOPERATIVE COMPLICATION; UNITED STATES;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; BENZIMIDAZOLES; BETA-ALANINE; DRUG APPROVAL; HUMANS; KIDNEY; LIVER; MORPHOLINES; POSTOPERATIVE COMPLICATIONS; PULMONARY EMBOLISM; PYRAZOLES; PYRIDONES; THIOPHENES; THROMBOEMBOLISM; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84860310835     PISSN: 03980499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0398-0499(11)70002-6     Document Type: Article

References (15)

1. Paikin JS, Eikelboom JW, Cairns JA, Hirsh J. New antithrombotic agents-insights from clinical trials. Nat Rev Cardiol 2010;7:498-509.
2. Samama M, Conard J, Horellou MH, Le Flem L, Guinet C, Depasse F. Deux nouveaux anticoagulants disponibles en 2010 - dabigatran etexilate et rivaroxaban: progrès attendus - problèmes posés. Ann Pharm Fr 2010;68:359-69.
3. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008;47:285-95.
4. Laux V, Perzborn E, Kubitza D, Misselwitz E. Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost 2007;33:515-23.
5. Mehta RS. Novel oral anticoagulants for prophylaxis and treatment of venous thromboembolism: part I (Factor Xa inhibitors) Expert Rev Hematol. 2010;3:227-241
6. Samama MM, Martinoli JL, Leflem L, Guinet C, Plu-Bureau G, Depasse F, et al. Assessment of laboratory assays to measure rivaroxaban, an oral direct factor Xa inhibitor. Thromb Haemost 2010;103:815-25.
7. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE. Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 2010;32:673-9.
8. Liesenfeld KH, Schäfer HG, Trocóniz IF, Tillmann C, Eriksson BI, Stangier J. Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis. Br J Clin Pharmacol 2006;62:527-37.
9. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008;36:386-99.
10. European Medicines Agency (EMEA). European public assessment report: Pradaxa [online]. Available from URL: http://www.emea. europa.eu/humandocs/PDFs/EPAR/pradaxa/H-829-PI-en.pdf.
11. Stangier J, Stähle H, Rathgen K, et al. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin [abstract no. P-W-672]. XXIst Congress, International Society of Thrombosis and Haemostasis ; 2007 Jul 6-12 ; Geneva [online].
12. Gross PL, Weitz JI. New anticoagulants for treatment of venous thromboembolism. Arterioscler Thromb Vasc Biol 2008;28:380-6.
13. Weinz C, Radtke M, Schmeer K, Kern A, Pleiss U. In vitro metabolism of BAY 59-7939, an oral, direct factor Xa inhibitor [Abstract 195]. Drug Metab Rev 2004;36 (Suppl 1):98 [Abstract 195].
14. Bayer Inc. Xarelto® (rivaroxaban 10 mg tablets): product monograph [online]. Available fromURL: http://www.bayerhealth. com/BayerHC/display.cfm/Object_ID=272&Article_ ID=56&expandMenu_ID=53&prevSubItem=5_52.
15. Stangier J, Stähle H, Rathgen K, et al. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug [abstract no. P-T-677]. XXIst Congress, International Society of Thrombosis and Haemostasis ; July 2007 ; Geneva.